Sökning: onr:"swepub:oai:DiVA.org:oru-61451" >
Intradermal HIV-1 D...
Intradermal HIV-1 DNA immunization using needle-free ZetajetTM injection followed by HIV-modified vaccinia virus Ankara vaccination is safe and immunogenic in Mozambican young adults : a phase I randomized controlled trial
-
- Viegas, Edna Omar (författare)
- Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Tembe, Nelson (författare)
- Instituto Nacional de Saúde, Maputo, Mozambique; Division of Clinical Microbiology, Department of Laboratory Medicine, Huddinge, Karolinska Institutet, Sweden; Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Nilsson, Charlotta (författare)
- Karolinska Institutet
-
visa fler...
-
- Meggi, Bindiya (författare)
- Instituto Nacional de Saúde, Maputo, Mozambique
-
- Maueia, Cremildo (författare)
- Instituto Nacional de Saúde, Maputo, Mozambique
-
- Augusto, Orvalho (författare)
- Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Stout, Richard (författare)
- Bioject Medical Technologies Inc, Tualatin OR, United States
-
- Scarlatti, Gabriella (författare)
- Institute for Research and Health Care (IRCCS), San Raffaele Scientific Institute, Milan, Italy
-
- Ferrari, Guido (författare)
- Department of Surgery and Molecular Genetics and Microbiology, Duke University Medical Center, Durham NC, United States
-
- Earl, Patricia (författare)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAD)/National Institutes of Health (NIH), Bethesda MD, United States
-
- Wahren, Britta (författare)
- Karolinska Institutet
-
- Andersson, Sören, 1957- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Laboratory Medicine, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden
-
- Robb, Merlin (författare)
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, The Military HIV Research Program, Walter Reed Army Institute of Research, Bethesda MD, United States
-
- Osman, Nafissa (författare)
- Universidade Eduardo Mondlane, Maputo, Mozambique
-
- Biberfeld, Gunnel (författare)
- Karolinska Institutet
-
- Jani, Ilesh (författare)
- Instituto Nacional de Saúde, Maputo, Mozambique
-
- Sandström, Eric (författare)
- Microbiology,Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- Mary Ann Liebert, 2018
- 2018
- Engelska.
-
Ingår i: AIDS Research and Human Retroviruses. - : Mary Ann Liebert. - 0889-2229 .- 1931-8405. ; 34:2, s. 193-205
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- We assessed safety and immunogenicity of HIV-DNA priming using ZetajetTM, a needle-free device intradermally followed by intramuscular HIV-MVA boosts, in 24 healthy Mozambicans. Volunteers were randomized to receive three immunizations of 600 µg (n = 10; 2 x 0.1mL) or 1200 µg (n = 10; 2 x 0.2mL) of HIV-DNA (3 mg/mL), followed by two boosts of 108pfu HIV-MVA. Four subjects received placebo saline injections. Vaccines and injections were safe and well tolerated with no difference between the two priming groups. After three HIV-DNA immunizations, IFN-γ ELISpot responses to Gag were detected in 9/17 (53%) vaccinees, while none responded to Env. After the first HIV-MVA, the overall response rate to Gag and/or Env increased to 14/15 (93%); 14/15 (93%) to Gag and 13/15 (87%) to Env. There were no significant differences between the immunization groups in frequency of response to Gag and Env or magnitude of Gag responses. Env responses were significantly higher in the higher-dose group (median 420 vs 157.5 SFC/million PBMC, p=0.014). HIV-specific antibodies to subtype C gp140 and subtype B gp160 were elicited in all vaccinees after the second HIV-MVA, without differences in titers between the groups. Neutralizing antibody responses were not detected. Two (13%) of 16 vaccinees, one in each of the priming groups, exhibited antibodies mediating antibody-dependent cellular cytotoxicity to CRF01_AE. In conclusion, HIV-DNA vaccine delivered intradermally in volumes of 0.1-0.2 mL using ZetajetTM was safe and well tolerated. Priming with the 1200 µg dose of HIV-DNA generated higher magnitudes of ELISpot responses to Env.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- HIV
- vaccine
- Mozambique
- HIV-DNA
- HIV-MVA
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Viegas, Edna Oma ...
-
Tembe, Nelson
-
Nilsson, Charlot ...
-
Meggi, Bindiya
-
Maueia, Cremildo
-
Augusto, Orvalho
-
visa fler...
-
Stout, Richard
-
Scarlatti, Gabri ...
-
Ferrari, Guido
-
Earl, Patricia
-
Wahren, Britta
-
Andersson, Sören ...
-
Robb, Merlin
-
Osman, Nafissa
-
Biberfeld, Gunne ...
-
Jani, Ilesh
-
Sandström, Eric
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
AIDS Research an ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet